Targeted Protein Degradation Market
Targeted Protein Degradation Market Scope:
Industry Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Targeted Protein Degradation Market Size and Growth
The targeted protein degradation market is experiencing significant growth, driven by advancements in drug discovery and increased R&D investments. The market size is projected to reach approximately $5 billion by 2025, fueled by rising demand for innovative therapies targeting diseases with high unmet needs and the emergence of new technologies in biopharmaceuticals.
Companies Covered
(Covid 19 Impact Covered)
◍ 5AM Venture Management LLC
◍ AbbVie Inc
◍ Almac Group
◍ Amgen Inc.
◍ Bayer AG
◍ Biogen Inc.
◍ C4 Therapeutics
◍ Cosmo Bio USA
◍ Covance Inc
◍ Eli Lilly and Company
◍ Gilead Sciences, Inc
◍ GlaxoSmithKline plc
◍ Merck KGaA
◍ Mission Therapeutics
◍ Novartis AG
◍ Pfizer Inc
◍ Promega
The Targeted Protein Degradation Market features key players like AbbVie, Amgen, and Novartis, utilizing novel TPD technologies to address diseases by degrading specific proteins. These companies enhance market growth through innovative drug development and collaborations. Notable sales include:
- AbbVie: ~$56 billion
- Amgen: ~$26 billion
- Gilead: ~$27 billion
Market Segmentation
By Application
Hospital
Research Institute
Request Sample Report
By Product
Oral
Intravenous
Others
Market Growth
Request Sample Report
$ X Billion USD
